Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human amniotic membrane (hAM) is a biological tissue graft derived from the innermost layer of the placenta, utilized for its regenerative, anti-inflammatory, and anti-fibrotic properties. In the treatment of medication-related osteonecrosis of the jaw (MRONJ), specifically stage II, it is applied as a cryopreserved graft following surgical debridement of necrotic bone. The membrane acts as a bioactive scaffold that promotes oral mucosal healing and bone repair by releasing a variety of growth factors (such as VEGF, EGF, and TGF-beta) and cytokines, and by providing a source of mesenchymal stem cells. The Centre Hospitalier Universitaire de Besancon is currently investigating the efficacy of hAM in the Phase II amniOST trial to improve healing outcomes in patients whose jaw necrosis was induced by antiresorptive or anti-angiogenic therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human amniotic membrane.